Pharmaceutical Intermediate Erlotinib

Product Details

Pharmaceutical Intermediate Erlotinib CAS-183322-18-1, 4-chloro-6 7-bis(2-methoxyethoxy) quinazoline powderis the key intermediate of the new anti-tumor drug erlotinib hydrochloride, and its properties are light yellow to off-white powder. Although Tarceva (erlotinib hydrochloride) tablets cannot be said to be a special drug, their unique efficiency in quickly relieving lung cancer symptoms has been unanimously recognized. Tarceva (erlotinib hydrochloride) tablets have been clinically proven to be a targeted therapy drug that can significantly prolong the survival of lung cancer patients. Anti-tumor effect can be achieved by inhibiting tumor cell growth or promoting tumor cell apoptosis. It is effective and well tolerated for all types of non-small cell lung cancer patients, without myelosuppression and neurotoxicity, and can significantly prolong survival and improve patients’ quality of life.

Health Benefits

Erlotinib itself blocks the signal transduction pathways of cancer cell proliferation, growth, and survival, thereby inducing cancer cell apoptosis and inhibiting tumor growth.

• Newly treated malignant glioma
• Recurrent malignant glioma
• Possible drug resistance mechanism of malignant glioma